CVM
Our research and development programs focus on exploiting the power of immunotherapy to develop new therapies that address the unmet medical needs of patients with cancer and infectious diseases. To that end, CEL-SCI is currently preparing to initiate a Global Phase III clinical trial of Multikine ® in patients with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity, a debilitating life-threatening disease, for which the overall five year survival rate has not materially improved over several decades.
Multikine ® , CEL-SCI’s flagship cancer product, is the first immunotherapeutic agent being developed as a first-line standard of care cancer treatment. Multikine ® is a different kind of weapon in the fight against cancer; one that harnesses our body’s natural ability to fight tumors.
Multikine ® is also the first of a new class of cancer immunotherapy drugs. It is the first comprehensive immunotherapy and the first Immune SIMULATOR.
Multikine ® is the only immunotherapy that is able to directly affect both the tumor cells themselves and activate a robust anti-tumor immune response.
CEL-SCI’s business strategy is to create genuinely new, valuable and unique therapies that meet unmet medical needs, as opposed to minor innovations to existing therapies or ‘me-too’ products. Multikine ® is such an innovation.
$1.32 (09/17/09)
